Packed Bed Lentiviral Vector Transfection With Batch-Perfusion Switching
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for large-scale manufacturing of lentiviral vectors in packed bed bioreactors face challenges in productivity, quality, reproducibility, and cost, with inefficiencies in transfection processes and medium exchange procedures.
Innovation Solution
A method combining batch and perfusion modes in a packed bed bioreactor for lentiviral vector production, using multi-plasmid DNA transient transfection with optimized DNA and PEI amounts, and a controlled medium exchange, reducing DNA consumption and production time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If multi-plasmid DNA transient transfection is performed in packed bed bioreactor using conventional methods, then lentiviral vectors can be manufactured at large scale, but productivity and quality are limited and costs are high
Solution Approach 1:
The patent optimizes critical process parameters including DNA amount (5-20 µg per 10 cm² surface area), PEI amount (1:1 to 1:5 ratio with DNA), transfection duration (4-72 hours), and medium exchange timing to maximize vector production while minimizing DNA consumption. This systematic parameter optimization resolves the contradiction between productivity and material consumption
Solution Approach 2:
The patent implements dynamic medium exchange protocols where fresh medium is added at specific time points (e.g., 24-48 hours post-transfection) based on transfection progression and vector release kinetics. This dynamic approach maintains optimal nutrient levels and removes inhibitory substances, thereby enhancing productivity without requiring excessive DNA input
2Productivity
If conventional transfection protocols are used in packed bed bioreactor, then lentiviral vectors can be produced, but the process duration is extended and costs increase
Solution Approach 1:
The patent performs preliminary optimization of transfection conditions including pre-mixing DNA with PEI to form complexes, pre-warming medium to optimal temperature, and establishing optimal cell confluence levels (70-90%) before transfection. These preliminary actions ensure that the transfection process proceeds efficiently within the optimized 4-72 hour window, reducing total process duration while maintaining high productivity
Solution Approach 2:
The patent identifies and skips non-productive time periods in the transfection protocol by implementing targeted medium exchanges at critical time points and harvesting vectors at optimal release times. This approach rushes through the productive phases while minimizing waiting time, thereby reducing overall process duration without sacrificing yield
3Quantity of substance
If high DNA amounts are used in transfection, then vector production can be maintained, but costs and DNA consumption increase
Solution Approach 1:
The patent establishes precise DNA dosage parameters (5-20 µg per 10 cm² surface area) and PEI ratios (1:1 to 1:5) that maximize transfection efficiency and vector yield while minimizing excess DNA. This optimized parameter range ensures adequate vector production without the DNA waste associated with conventional high-DNA protocols
Solution Approach 2:
The patent implements feedback mechanisms where transfection efficiency is monitored (e.g., through reporter gene expression or p24 antigen levels) and subsequent medium exchanges and harvesting are adjusted based on observed vector release kinetics. This feedback approach ensures that DNA is used efficiently to produce the required vector yield without unnecessary excess
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to the development of a method for the manufacturing of LVV vectors in a packed bed bioreactor by multi-plasmid transient DNA transfection. More particularly, the present invention discloses and claims a process in which steps applied in perfusion or in batch mode are combined to obtain an effective process. Moreover, the invention identifies an effective range of total DNA to be successfully used in the step of transient transfection in a packed bed bioreactor for the manufacturing of lentiviral vectors.